BEIJING, July 8, 2025 /PRNewswire/ -- On July 3, 2025 Global Digital Economy Conference was grandly held in Beijing. As part of the conference's signature "First Launch Global Debut" segment, iSoftStone officially introduced its new overseas brand, iSoftStone Digital, to the international market. This milestone marks the company's entry into "Going Global Expansion2.0" strategy. With a renewed positioning of driving global client value through digital technology innovation, iSoftStone Digital is opening a new chapter in its international development journey.
At the launch ceremony, Mr. Liu Huifu, Director and Chief Technology Officer; Mr. Han Zhimin, President of Computing Products and Smart Electronics Business; Mr. Huang Li, President of International Business; Mr. Yin Lu, Vice President; and Mr. Li Chuan, Vice President jointly witnessed the new era of "iSoftStone Digital", marking a significant milestone in the company's global expansion strategy.
As a Chinese leading enterprise in full-stack intelligent products and services, iSoftStone has always committed to global expansion, identifying "international growth" as one of its four core strategies. Over the past twenty years, the company has steadily built a global business network spanning four key regions: Southeast Asia, the Middle East, Japan, and North America. The release of this new brand is another important milestone in iSoftStone's overseas development. With a fresh brand identity, the company aims to further empower Chinese enterprises going abroad and support global clients in their digital transformation efforts.
During the launch ceremony, Mr. Yin Lu delivered a comprehensive interpretation of the brand's strategic positioning and significance. He stated, "iSoftStone Digital not only carries two decades of iSoftStone's innovation and global vision, but also represents our firm commitment to empowering global clients with digital technology and building a better future together." Moving forward, iSoftStone will empower global clients with seven strategic digital solutions and innovative products from its proprietary hardware brand MECHREVO.
Later, five key leaders took the stage together, placed their handprints on the brand activation panel, marking the official launch of iSoftStone Digital.
iSoftStone Digital aims to enhance its global presence by integrating resources and accelerating innovation. The company will focus on creating a strong outbound ecosystem, supporting enterprises in their international growth, and becoming a benchmark for Chinese tech firms worldwide. With an emphasis on collaboration, iSoftStone Digital is committed to advancing the global digital economy.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Global Debut! iSoftStone Digital Officially Launches as iSoftStone's New Overseas Brand
FREMONT, Calif., Jan. 13, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay. This innovative solution enables simultaneous quantitative measurement of five critical blood-based biomarkers relevant to the Alzheimer's Association recommended guidelines: brain-derived phosphorylated tau 217 (BD-pTau217), neurofilament light chain (NfL), amyloid-beta 42 (Aβ42), glial fibrillary acidic protein (GFAP), and APOE4 (carrier status), all from a single blood or plasma sample.
The NULISAqpcr AD 5-plex Assay consolidates key biomarkers into a single multiplexed format, delivering unmatched sensitivity, specificity, and ease of use. By incorporating BD-pTau217, Aβ42, NfL, and GFAP, the assay enables robust monitoring of amyloid and tau pathology, neurodegeneration, and inflammation, while accurately determining APOE4 carrier status—the strongest genetic risk factor for Alzheimer's disease. Together, these capabilities create a powerful tool for both translational and clinical research, and its relevance extends beyond Alzheimer's disease to other neurodegenerative and cognitive disorders.
"The launch of the NULISAqpcr AD 5-plex Assay marks a significant milestone in our efforts to deliver precision proteomics solutions for neurodegenerative disease," said Dr. Yuling Luo, founder, chairman and chief executive officer of Alamar. "By combining these critical protein targets into a single assay with a streamlined workflow, we are empowering the neuroscience community to advance screening, early detection and precision diagnoses for Alzheimer's disease."
"Blood-based biomarkers are redefining Alzheimer's research, providing an accurate, cheaper and more accessible means of establishing early diagnosis and aiding determination of eligibility for therapies," said Dr. Steven Williams, chief scientific officer of Alamar. "Traditional single-plex assays can measure these biomarkers individually, but require multiple tests to provide a comprehensive view of the disease. With NULISA™ it is now possible to measure multiple Alzheimer's-related proteins in blood, each offering unique insights into the underlying pathophysiology."
Alamar is dedicated to collaborating with researchers, clinicians, and industry partners to unlock precision proteomics and improve outcomes for patients affected by Alzheimer's disease and other neurodegenerative conditions. The NULISAqpcr AD 5-plex Assay is available today as a service through our Technology Access Program.
For more information about the NULISAqpcr AD 5-plex Assay and Alamar's full portfolio of precision proteomic solutions, visit www.alamarbio.com.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research
Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research
